Trial Profile
An Explorative Phase 2, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Trial of Two Dosing Regimens of AP214 for the Prevention of Kidney Injury in Patients Undergoing Cardiac Surgery
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2014
Price :
$35
*
At a glance
- Drugs Modimelanotide (Primary)
- Indications Acute kidney injury
- Focus Adverse reactions; Therapeutic Use
- Sponsors Action Pharma
- 17 Sep 2014 New trial record